Compare Apple Inc (AAPL) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Johnson & Johnson — how do they compare? Apple Inc trades at $303.96 (market cap $4.45T), while Johnson & Johnson trades at $257.23 (market cap $626.09B). The key difference: Apple Inc is far larger — about 7.1× Johnson & Johnson's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| AAPL | JNJ | |
|---|---|---|
Market Cap | $4.45T | $626.09B |
Volume | 100,358,844 | 6,156,228 |
Sector | Technology | Health |
52-Week High | $340.08 | $267.24 |
52-Week Low | $224.90 | $172.78 |
Enterprise Value | $4.47T | $654.37B |
Dividend Yield | 0.35% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and near-term support at $306. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union disputes and potential Q3 earnings pressure.
Outlook remains positive driven by AI opportunities and a massive device ecosystem, but risks include weaker iPhone sales, regulatory scrutiny, and union tensions. The stock offers growth potential with solid cash flow, yet investors should weigh near-term headwinds against long-term strengths.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
